The asthma medication reduces congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in a ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

Vasomotor rhinitis is a cause of runny nose and congestion not related to allergies or an infection. Learn about the symptoms ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Neffy (epinephrine nasal spray) 1mg is approved for the emergency treatment of type 1 allergic reactions in children aged 4 ...

Nasal Polyps Treatment Market Research Report The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030 ...

A new study published in the European Archives of Oto-Rhino-Laryngology revealed that serum 25(OH)D deficiency is an ...

OptiNose (NASDAQ:OPTN) stock surges 61% as Paratek Pharmaceuticals agrees to a $330M acquisition. Read mroe here.

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to ...